These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9391679)

  • 1. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine.
    Liau-Chu M; Theis JG; Koren G
    Ann Pharmacother; 1997 Nov; 31(11):1287-91. PubMed ID: 9391679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
    Theis JG; Liau-Chu M; Chan HS; Doyle J; Greenberg ML; Koren G
    J Clin Oncol; 1995 Oct; 13(10):2508-16. PubMed ID: 7595701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for preventing reactions secondary to Cremophor EL.
    Michaud LB
    Ann Pharmacother; 1997 Nov; 31(11):1402-4. PubMed ID: 9391700
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL.
    Howrie DL; Ptachcinski RJ; Griffith BP; Hardesty RJ; Rosenthal JT; Burckart GJ; Venkataramanan R
    Drug Intell Clin Pharm; 1985 Jun; 19(6):425-7. PubMed ID: 4006735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.
    Ehinger KH; Hansson MJ; Sjövall F; Elmér E
    Clin Drug Investig; 2013 Jan; 33(1):25-34. PubMed ID: 23179472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL.
    Roman ID; Monte MJ; Esteller A; Jimenez R
    Transplantation; 1989 Oct; 48(4):554-8. PubMed ID: 2799907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
    Szebeni J; Muggia FM; Alving CR
    J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct vasoconstrictor effects of sandimmune (cyclosporine A) are mediated by its vehicle cremophor EL: inhibition by the thromboxane A2/prostaglandin endoperoxide receptor antagonist ifetroban.
    Lodge NJ
    J Pharmacol Exp Ther; 1994 Nov; 271(2):730-4. PubMed ID: 7965789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine.
    Ebo DG; Piel GC; Conraads V; Stevens WJ
    Ann Allergy Asthma Immunol; 2001 Sep; 87(3):243-5. PubMed ID: 11570623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of cyclosporin and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart.
    Mankad P; Spatenka J; Slavik Z; O'Neil G; Chester A; Yacoub M
    Cardiovasc Drugs Ther; 1992 Feb; 6(1):77-83. PubMed ID: 1576098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL.
    Besarab A; Jarrell BE; Hirsch S; Carabasi RA; Cressman MD; Green P
    Transplantation; 1987 Aug; 44(2):195-201. PubMed ID: 3629683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cremophor EL Alters the Plasma Protein Binding and Pharmacokinetic Profile of Valspodar in Rats.
    Binkhathlan Z
    Drug Res (Stuttg); 2017 Oct; 67(10):591-595. PubMed ID: 28628923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A.
    Aliabadi HM; Mahmud A; Sharifabadi AD; Lavasanifar A
    J Control Release; 2005 May; 104(2):301-11. PubMed ID: 15907581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
    Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
    J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine-induced anaphylaxis.
    Kuiper RA; Malingré MM; Beijnen JH; Schellens JH
    Ann Pharmacother; 2000; 34(7-8):858-61. PubMed ID: 10928395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the cyclosporine vehicle, cremophor EL, on renal microvascular blood flow in the rat.
    Abraham JS; Bentley FR; Garrison RN; Cryer HM
    Transplantation; 1991 Jul; 52(1):101-5. PubMed ID: 1858136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hemodynamic effects of Cremophor-EL.
    Bowers VD; Locker S; Ames S; Jennings W; Corry RJ
    Transplantation; 1991 Apr; 51(4):847-50. PubMed ID: 2014541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.
    Liu B; Gordon WP; Richmond W; Groessl T; Tuntland T
    Eur J Pharm Sci; 2016 May; 87():52-7. PubMed ID: 26499309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.